NKTX [NASD]
Nkarta, Inc.
Index- P/E- EPS (ttm)-2.68 Insider Own0.80% Shs Outstand48.63M Perf Week-0.92%
Market Cap436.54M Forward P/E- EPS next Y-2.89 Insider Trans-17.81% Shs Float45.32M Perf Month-29.82%
Income-104.10M PEG- EPS next Q-0.64 Inst Own92.80% Short Float / Ratio12.76% / 12.34 Perf Quarter-39.68%
Sales- P/S- EPS this Y6.40% Inst Trans-6.71% Short Interest5.78M Perf Half Y-42.92%
Book/sh8.21 P/B1.05 EPS next Y-11.20% ROA-26.20% Target Price31.82 Perf Year-42.54%
Cash/sh7.72 P/C1.11 EPS next 5Y- ROE-32.00% 52W Range7.55 - 20.35 Perf YTD-44.04%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-57.79% Beta-
Dividend %- Quick Ratio15.20 Sales past 5Y- Gross Margin- 52W Low13.77% ATR0.61
Employees146 Current Ratio15.20 Sales Q/Q- Oper. Margin- RSI (14)29.80 Volatility5.94% 6.62%
OptionableYes Debt/Eq0.00 EPS Q/Q14.20% Profit Margin- Rel Volume1.46 Prev Close8.37
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume468.64K Price8.59
Recom1.60 SMA20-13.86% SMA50-27.04% SMA200-32.52% Volume683,242 Change2.63%
Oct-10-22Initiated Canaccord Genuity Buy $25
Jul-28-22Initiated Needham Buy $26
Jul-18-22Initiated SVB Leerink Outperform $30
Mar-11-22Initiated Raymond James Outperform $17
Mar-08-22Initiated H.C. Wainwright Buy $25
Jan-06-22Initiated William Blair Outperform
Nov-18-21Initiated SMBC Nikko Outperform $50
Jul-16-21Initiated Oppenheimer Outperform $75
Aug-04-20Initiated Stifel Buy $41
Aug-04-20Initiated Mizuho Buy $34
Show Previous Ratings
Dec-02-22 04:02PM
Nov-09-22 04:02PM
Nov-07-22 08:52AM
Nov-02-22 08:02AM
Sep-24-22 09:34AM
07:30AM Loading…
Sep-23-22 07:30AM
Aug-11-22 04:02PM
Aug-10-22 08:42AM
Aug-07-22 06:15AM
Jul-25-22 04:31PM
Jul-18-22 02:46PM
Jun-14-22 07:14AM
Jun-07-22 09:55AM
May-31-22 07:02AM
May-18-22 12:00PM
09:55AM Loading…
09:55AM
May-16-22 04:02PM
May-12-22 04:02PM
May-09-22 04:02PM
May-06-22 05:30PM
May-02-22 10:45AM
Apr-28-22 04:01PM
10:18AM
Apr-25-22 11:19PM
06:04PM
05:44PM
04:09PM
04:01PM
03:52PM
10:49AM
08:34AM Loading…
08:34AM
08:19AM
07:12AM
07:00AM
Apr-22-22 04:10PM
Apr-17-22 08:54AM
Apr-08-22 01:25PM
07:58AM
Apr-04-22 12:00PM
Mar-29-22 08:02AM
Mar-22-22 10:00AM
Mar-17-22 04:02PM
Mar-08-22 04:35PM
Mar-01-22 11:00AM
Feb-10-22 08:02AM
Jan-05-22 06:56AM
Dec-16-21 08:02AM
Dec-13-21 04:02PM
Nov-25-21 07:35AM
Nov-15-21 10:47AM
Nov-12-21 07:15AM
Nov-10-21 04:01PM
Nov-04-21 08:04AM
Oct-08-21 08:11AM
Oct-07-21 04:01PM
09:24AM
Oct-01-21 08:08AM
Sep-14-21 08:32AM
Aug-12-21 04:02PM
Jul-14-21 09:07AM
07:00AM
Jun-16-21 07:00AM
Jun-14-21 07:01AM
Jun-06-21 12:16PM
May-25-21 07:30AM
May-13-21 04:02PM
May-07-21 11:38AM
May-06-21 04:01PM
Apr-28-21 08:02AM
Mar-25-21 04:03PM
Feb-17-21 04:03PM
Dec-09-20 03:46PM
Dec-07-20 03:33PM
Nov-12-20 04:03PM
04:02PM
Nov-09-20 08:02AM
Nov-05-20 04:02PM
Oct-12-20 11:03AM
Oct-05-20 04:02PM
Sep-29-20 08:02AM
Sep-08-20 04:02PM
Aug-20-20 04:02PM
Jul-31-20 04:42PM
Jul-14-20 04:39PM
04:15PM
Jul-10-20 11:30AM
08:09AM
12:44AM
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brandenberger RalphChief Technical OfficerOct 06Option Exercise3.898423,2758,642Oct 07 06:44 PM
Brandenberger RalphChief Technical OfficerOct 06Sale14.0284211,8057,800Oct 07 06:44 PM
HASTINGS PAUL JChief Executive OfficerSep 29Sale13.004986,474250,461Sep 30 04:30 PM
HASTINGS PAUL JChief Executive OfficerSep 28Sale13.0323,376304,615250,959Sep 30 04:30 PM
HASTINGS PAUL JChief Executive OfficerSep 21Sale13.016,12679,717274,335Sep 22 05:32 PM
Trager JamesChief Scientific OfficerAug 15Option Exercise3.895,00019,45067,172Aug 17 04:21 PM
Mahmood NadirSee RemarksAug 15Option Exercise3.897,50029,17553,588Aug 17 04:17 PM
Brandenberger RalphChief Technical OfficerAug 15Option Exercise3.8911,00042,79018,800Aug 17 04:20 PM
Mahmood NadirSee RemarksAug 15Sale18.037,500135,21546,088Aug 17 04:17 PM
Trager JamesChief Scientific OfficerAug 15Sale17.535,00087,65662,172Aug 17 04:21 PM
Brandenberger RalphChief Technical OfficerAug 15Sale17.6411,000194,0527,800Aug 17 04:20 PM
Mahmood NadirSee RemarksAug 08Option Exercise3.897,50029,17553,588Aug 10 07:03 PM
Brandenberger RalphChief Technical OfficerAug 08Option Exercise2.6011,59330,19919,393Aug 10 07:05 PM
Brandenberger RalphChief Technical OfficerAug 08Sale15.5111,593179,7837,800Aug 10 07:05 PM
Mahmood NadirSee RemarksAug 08Sale15.327,500114,90046,088Aug 10 07:03 PM
Mahmood NadirSee RemarksJul 25Option Exercise3.897,50029,17553,588Jul 26 08:14 PM
Brandenberger RalphChief Technical OfficerJul 25Option Exercise0.413,0001,23010,800Jul 26 08:15 PM
Mahmood NadirSee RemarksJul 25Sale13.407,500100,48046,088Jul 26 08:14 PM
Brandenberger RalphChief Technical OfficerJul 25Sale13.413,00040,2307,800Jul 26 08:15 PM
Brandenberger RalphSr. VP, Technical OperationsJun 03Option Exercise3.694,14015,2789,440Jun 07 04:01 PM
Brandenberger RalphSr. VP, Technical OperationsJun 03Sale15.004,14062,1005,300Jun 07 04:01 PM
George SimeonDirectorApr 28Buy15.001,333,33319,999,995666,667Apr 29 04:27 PM
RA CAPITAL MANAGEMENT, L.P.DirectorApr 26Buy15.002,200,00033,000,0007,805,129Apr 28 04:32 PM